ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project
ProBioGen AG, a premier service & technology provider for complex therapeutic glycoproteins, today announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company, harnessing the power of the immune system to develop treatments for cancer.
Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate.
“Tizona Therapeutics selected ProBioGen based on its excellent CHO.Right® development and manufacturing platform,” said Christine O’Brien, Vice President of Program Management at Tizona Therapeutics. “ProBioGen’s collaborative approach, high standard for delivering quality product and timely execution of our project again make them an ideal partner for Tizona.”
Dr. Volker Sandig, ProBioGen’s Chief Scientific Officer added, “ProBioGen’s and Tizona’s teams work together really well and ProBioGen is committed to delivering a quality product candidate within best-in-class development timelines to support potential clinical trials for Tizona Therapeutics.”
About ProBioGen AG – www.probiogen.de
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen’s CHO-RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.